# Mesenchymal Stem Cells for the Treatment of MS

> **NCT00781872** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Injection of autologous bone marrow derived mesenchymal stem cells

## Key facts

- **NCT ID:** NCT00781872
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00781872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00781872, "Mesenchymal Stem Cells for the Treatment of MS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00781872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*